期刊文献+

氯吡格雷在预防和治疗冠心病中的疗效及安全性分析 被引量:7

The Analysis of Efficacy and Safety of Clopidogrel in Preventing and Treating Coronary Heart Disease
下载PDF
导出
摘要 目的:分析氯吡格雷在预防和治疗冠心病中的疗效及安全性.方法:收集某院2010年1月-2014年2月期间诊治的162例冠心病患者作为研究对象,根据患者的治疗药物将其分为氯吡格雷组(81例)与阿司匹林组(81例),阿司匹林组患者则采用阿司匹林治疗,氯吡格雷组采用氯吡格雷治疗,观察患者的总体治疗效果、不良心脏事件、支架内血栓发生情况及治疗前后的血脂水平改善情况.结果:比较两组患者的总体疗效发现,氯吡格雷组明显优于阿司匹林组(P 〈0.05),且氯吡格雷组不良心脏事件、支架内血栓发生率明显低于阿司匹林组(P 〈0.05),血脂水平改善情况明显优于阿司匹林组(P 〈0.05).结论:氯吡格雷在预防和治疗冠心病中具有良好的临床疗效,并能够减少不良心脏事件、支架内血栓的发生,具有很高的安全性. Objective:To analyze the efficacy and safety of clopidogrel in preventing and treating coronary heart disease.Methods:Select 162 cases of coronary heart disease patients received by a hospital during the period from January 2010 to February 2014 as subjects.Divide them into two groups according to the medicine they take,the clopidogrel group(81cases)and aspirin group(81cases).The clopidogrel group was given clopidogrel treatment while the aspirin group was given aspirin treatment.The whole curative effect,adverse heart accident,incidence of stent thrombosis and blood lipid level improvement of patients are observed.Results:The whole curative effect in the clopidogrel group was significantly better than that in the aspirin group(P<0.05).The adverse heart accident and incidence of stent thrombosis in the clopidogrel group were significantly lower than those in the aspirin group(P<0.05).The blood lipid level improvement of patients in the clopidogrel group was significantly better than that in the aspirin group(P <0.05).Conclusion:Clopidogrel has significant clinical effect in preventing and treating coronary heart disease.It can reduce adverse heart accidents and incidence of stent thrombosis and is highly safe.
作者 李俊 戎晓敏
出处 《数理医药学杂志》 2016年第2期225-226,共2页 Journal of Mathematical Medicine
关键词 氯吡格雷 冠心病 疗效 安全性 clopidogrel coronary heart disease efficacy safety
  • 相关文献

参考文献6

二级参考文献41

  • 1Eric L Eisenstein, DBA,Kevin J. Anstrom, PhD,David F. Kong, MD,Linda K. Shaw, MS,Robert H. Tuttle, MSPH,Daniel B. Mark, MD, MPH,Judith M. Kramer, MD, MS,Robert A. Harrington, MD,David B. Matchar, MD,David E. Kandzari, MD 1,Eric D. Peterson, MD, MPH,Kevin A. Schulman, MD,Robert M. Califf, MD,李呈亿(译),David E. Kandzari, MD.氯吡格雷的使用与药物洗脱支架植入后远期临床结果[J].美国医学会杂志(中文版),2007,26(3):131-139. 被引量:59
  • 2陆再英,钟南山,主编.内科学[M].第7版.北京:人民卫生出版社,2007.282.
  • 3Stockl KM, Le L, Zakharyan A, et al. Risk of rehospitalization for patients using clopidogrel with a proton pump inhibitor [ J]. Arch Intern Med, 2010,170(8) :704-710.
  • 4Ray WA, Murray KT, Griffin MR, et al. Outcomes with concurrent use of clopidogrel and proton pump inhibitors: a cohort study [ J]. Ann Intern Med, 2010,152(6) :337-345.
  • 5Siller-Matula JM, Spiel AO, Lang IM, et al. Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel [ J ]. Am Heart J, 2009,157( 1 ) :148.
  • 6Xu F, Lv S, Chen Y, et al. Macrophage inflammatory protein - 1 and fibrinogen are synergistic predictive markers of prognosis of interme- diate coronary artery hsions [J]. Cardiology, 2012, 121 (1) : 12 - 19.
  • 7Gupta E, Bansal D, Sotos J, et al. Risk of adverse clinicaloutcomes with concomitant use of clopidogrel and protonpump inhibitors following percutaneous coronary intervention[J]. Dig Dis Set, 2010,55(7): 1964.
  • 8Bertrand M E, Simoons M L,Fox K A, et al. Managementof acute coronary syndromes: acute coronary syndromeswithout persistent segment elevation: recommendation ofthe task force of the European society of cardiolc^yfj ]. EurHeart J, 2000, 21(7): 1406.
  • 9Leong L C, Sim L S, Lee Y S, et al. A prospective study tocompare the diagnostic performance of breast elastographyversus conventional breast ultrasound[J]. Clin Radiol, 2010,65(11): 887.
  • 10Yasuda H, Yamada M, Sawada S, et al. Upper gastroin-testinal bleeding in patients receiving dual anti ~ platelet ther-apy after coronary stentingf J]. Interm Med, 2009,48(19):1725.

共引文献127

同被引文献31

引证文献7

二级引证文献22

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部